Compare Vanguard Total Bond Market Index Fund ETF (BND) vs Johnson & Johnson (JNJ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Vanguard Total Bond Market Index Fund ETF vs Johnson & Johnson — how do they compare? Vanguard Total Bond Market Index Fund ETF trades at $72.34, while Johnson & Johnson trades at $259.29 (market cap $626.09B). The key difference: Johnson & Johnson pays a 2.06% dividend while Vanguard Total Bond Market Index Fund ETF pays none, and Johnson & Johnson is trading nearer its 52-week high, Vanguard Total Bond Market Index Fund ETF nearer its low. Which is the better fit depends on your goals.
| BND | JNJ | |
|---|---|---|
52-Week High | $75.17 | $267.24 |
52-Week Low | $72.15 | $172.78 |
Market Cap | — | $626.09B |
Volume | — | 6,156,228 |
Sector | — | Health |
Enterprise Value | — | $654.37B |
Dividend Yield | — | 2.06% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BND trades at $72.36, up 0.29% today, amid a bearish technical outlook with moving averages signaling sell pressure and oscillators neutral. The ETF shows consistent dividend distributions, with recent payouts of $0.25 and $0.24. News highlights institutional activity, including Boston Standard Wealth reducing its stake by 30.6% in Q2 2026 (SEC filing, 2026-08-05), while broader bond ETF inflows reached nearly $300 billion in H1 2026 (Zacks Investment Research, 2026-08-06).
The outlook remains cautious due to technical weakness and interest rate sensitivity, but BND offers income stability through dividends. Risks include Treasury yield volatility and inflation data impacts, yet it serves as a core fixed-income holding for diversification amid market uncertainty.
Johnson & Johnson (JNJ) trades at $261.81, up 0.99% on the day and near its 52-week high. The stock exhibits bullish technical signals with strong moving average support, while fundamentals show robust profitability with a net income margin of 21.48% and consistent dividend growth. Recent earnings have mostly beaten expectations, and the company maintains a solid balance sheet with $24.52 billion in cash.
The outlook for JNJ remains positive, supported by analyst consensus and a price target of $284.50. Key opportunities include its defensive healthcare positioning and pipeline strength, though risks involve patent expirations and legal headwinds. The stock offers a stable investment with growth potential in a volatile market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Vanguard Total Bond Market Index Fund ETF
This index measures the performance of a wide spectrum of public, investment-grade, taxable, fixed income securities in the US, including government, corporate, and international dollar-denominated bonds, as well as mortgage-backed and asset-backed securities-all with maturities of more than 1 year. All of the fund's investments will be selected through the sampling process, and at least 80% of its assets will be invested in bonds held in the index.
Read more on BND →About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →
